Загрузка...
Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of (177)Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells
SIMPLE SUMMARY: The peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTA-octreotate (LuTate) is recommended for neuroendocrine tumors (NETs) which overexpress somatostatin receptors (SSTR). A combination of LuTate with chemotherapy improves its objective response in NET patients, and here...
Сохранить в:
| Опубликовано в: : | Cancers (Basel) |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7828052/ https://ncbi.nlm.nih.gov/pubmed/33435224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13020232 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|